High Growth Reported for The Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2008

Reportlinker.com announces that a new market research report related to the Pharmaceu industry is available in its catalogue.

The Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2008

http://www.reportlinker.com/p091996/The-Pharmaceutical-Wholesale-and-Distribution-Industry-Outlook-and-Analysis-2008.html

The major problem facing the Wholesale & Distribution industry is its low profit margin which is in the region of only 1-2%. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. As generics are priced lower than their branded counterparts, the actual dollar profit on them taken by W&D companies, for their movement, is reduced. In the light of this, other key factors such as new pricing and distribution models are also discussed in more detail. Other important issues that are affecting the industry and discussed in detail include:

1. Drug Counterfeiting

2. Direct-to-Pharmacy Distribution

3. Parallel Trade

4. Canada and US Drug Reimportation

5. Internet drugs: Mail Order and On-line Pharmacies.

The objectives of this report are to understand the W&D industry, why it occurs, who it affects, different natures of wholesale-distribution and what kinds of strategies are involved. Wholesale-Distribution has both pros and cons for different healthcare stakeholders. Wholesale-Distribution is a complex area, where there are many “grey” areas.

In particular, The Pharmaceutical Wholesale and Distribution Sector concentrates on the following essential aspects of the industry:

– Discussion of the current W&D market

– Forecast of the big three US wholesalers from 2008-2013

– Drivers and restraints facing the W&D market

– Opportunities and threats facing the W&D market

– Commercial prospects for the W&D market

– Discussion of unmet needs

This report examines the industry critically through a comprehensive review of available information, including that from commercial databases and other highly relevant sources, including SWOT analysis. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion. Why you should buy this report:

– To receive a comprehensive analysis of the prospects for the W&D market

– To discover predicted revenues, growth rates and other key metrics for the big three US wholesalers from 2008-2013

– To determine key activities of leading pharmaceutical manufacturers

– To determine the forces that influence the W&D market

– Competitive characteristics of the market

– Drivers

– Restraints

– Strengths, weaknesses, opportunities and threats (SWOT analysis)

– To find out where the W&D industry is heading – both technologically and commercially

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

 Chapter 1 Executive Summary  1.1 Continual Low Profit Margins is the Major Problem for the W&D Industry  1.2 Parallel Trade Will Not Go Away  1.3 Canada and US Drug Reimportation Will Not Develop Further  1.4 Direct-to-Pharmacy Distribution Will Cut Out the ‘Middle Man’  1.5 Drug Counterfeiting is a Problem for Western Markets but can be     Controlled  1.6 Internet drugs (Mail Order and On-line Pharmacies) will Show     Increasing Growth  1.7 The Increasing Genericisation of all Drug Markets Remains a Threat to     the W&D Industry  1.8 Aims, Scope and Format of the Report  Chapter 2 Introduction  2.1 The Wholesale and Distribution Industry – Overview  2.1.1 Drug Wholesalers – More Than Just a Middleman  2.1.2 Roles and Functions of the W&D Companies  2.1.3 Distinctive Features and Difficulties Facing the Pharmaceutical       UK Wholesale Market  2.2 There are Four Different Types of Wholesaler  2.2.1 Full-line wholesalers  2.2.2 Short-line wholesalers  2.2.3 Pre-wholesaling is Predominantly a European Experience  2.2.4 Secondary Wholesaler’s and their Effect on the Pharmaceutical       Industry  2.3 The Supply Chain: The Importance of an Efficient Supply Chain for     Competitive Operations Within the Pharmaceutical Industry  2.3.1 The Internet is Rapidly Becoming an Integral Part of the W&D       Supply Chain  2.4 The Big Three Dominates the US W&D Industry  2.5 The Top Ten Countries in the Pharmaceutical Industry – Retail &      Hospital Sector Breakdown  Chapter 3 Forces Affecting the Pharmaceutical Wholesale-Distribution  Industry  3.1 SWOT analysis  3.1.1 Market Drivers  3.1.2 Market Restraints  3.2 High Demand for Pharmaceutical Products Will Drive the     Wholesale-Distribution Industry  3.3 The Efficiency of W&D Operations Helps to Keep Drug Prices Low  3.4 Fee-For-Service is Becoming Predominant in the US But Will Not     Affect European W&D  3.5 Globalisation Will Provide an Opportunity to Expand the     Wholesale-Distribution Industry – However it Could Increase More     Parallel Trading and Drug Counterfeits  3.6 Continual Low Profit Margins is the Major Problem for the W&D     Industry  3.6.1 The Increasing Genericisation of all Drug Markets Remains a Threat       to the W&D Industry Profit Margin  3.7 The European W&D Industry is Hampered by Strict Drug Price Controls  3.8 Drug Counterfeiting is a Problem for Western Markets but Can be     Controlled  3.9 Would Market Harmonisation in the EU Eliminate the Practice of     Parallel Trade?  3.9.1 The Exhaustion of IPR Allows for the Importation of Drugs  3.10 Direct-to-consumer distribution channels will diminish the role       of wholesalers  3.11 Structural Changes Within the European Pharmaceutical Markets      Affecting the Wholesale & Distribution Industry  3.12 W&D and Price Regulation in India  3.13 Antimicrobial Drug Supply and Distribution in the Developing      Countries  Chapter 4 Parallel Trade in the W&D Industry  4.1 What is Parallel Trade and Why Does it Exist?  4.2 Pricing in the Pharmaceutical Industry  4.2.1 Factors that Influence Pricing  4.2.2 Price Differentials  4.2.3 Pricing is Not the Only Factor in Determining the Parallel Trade       Potential for a Drug  4.2.4 The Repackaging of Pharmaceuticals is an Important Aspect of       Parallel Trade  4.3 Exhaustion of Rights  4.3.1 National Exhaustion  4.3.2 Regional Exhaustion  4.3.3 International Exhaustion  4.3.4 Intellectual Property Rights  4.4 Parallel Trade is Predominantly a European Activity  4.5 The UK is the Largest Importer of Parallel Traded Drugs  4.5.1 The Method of Parallel Trade Importing into the UK  4.5.2 The Regulation of UK Parallel Trade  4.6 The Arguments For and Against Parallel Trade  4.6.1 The Drug Company’s Arguments Against Parallel Trade are Weak  4.7 EU Drug Price Harmonisation is Unlikely  Chapter 5 Drug Counterfeits – A Major Problem in the W&D Industry  5.1 The Legal Definitions of a Counterfeit Drug  5.1.1 Grouping Counterfeits  5.2 Prevalence of Counterfeiting  5.3 The Economic and Healthcare Cost of Drug Counterfeiting  5.3.1 The Economic Cost of Drug Counterfeiting  5.3.2 The Health Cost of Drug Counterfeiting  5.3.3 The Most Commonly Counterfeited Drugs by Country Region  5.3.4 Counterfeit Drugs Thrive Through Lack of Adequate and       Enforceable Legislation  5.4 Counterfeit Drugs is Not Just a Developing World Problem  5.5 Counterfeit Lipitor Dispersed Through the UK Supply Chain  5.6 Global Reports of Counterfeit Medicines  5.7 Moving Counterfeit Drugs into the Supply Chain  5.7.1 The Distribution Network as the Place of Entry for Counterfeit       Drugs  5.8 The Detrimental Effects of Counterfeit Drugs on Business Development  5.8.1 The Effect of Counterfeit Drugs on Consumers  5.8.2 The Effect of Counterfeit Drugs on Drug Manufacturers  5.8.3 The Effect of Counterfeit Drugs on Health Care Providers  5.8.4 The Effect of Counterfeit Drugs on Governments  5.9 The Four Types of Counterfeit Drugs  5.10 The Complexity of Wholesale and Distribution Routes Aids the      Counterfeiter  5.11 The Regulatory Strategies in Combating Drug Counterfeiting  5.12 The Technical Strategies in Combating Counterfeit Drugs  5.12.1 Holograms as Anti-Counterfeiting Devices  5.12.2 Security Inks as Anti-Counterfeit Devices  5.12.3 Micro Tags as Anti-Counterfeit Devices  5.12.4 Radio Frequency Identification Tags (RFID) as Anti-Counterfeit        Devices  Chapter 6 Fee-For-Service Pricing Model in the Pharmaceutical           Wholesaling Industry  6.1 What is the Fee-For-Service Pricing Model?  6.1.1 Why Switch to This Pricing Model?  6.2 Advantages and Disadvantages for the Fee-For-Service Pricing Strategy  6.3 Drug Manufacturers Will Want an Incentive to Shift to Fee-For-Service  6.4 Fee-For-Service is a Risk for the W&D Industry  6.5 The US Big Three W&D Companies Have Prepared for Fee-For-Service  6.6 Inventory Management Agreements (IMAs) are the Fee-For-Service      Agreements  6.6.1 The Experience of Fee-For-Service/IMAs is Limited  6.7 Fee-For-Service in the US and Europe Compared  6.8 US Based Cardinal Health Signs Fee-For-Service Deal with Eli Lilly  6.9 AmerisourceBergen and McKesson Say Fee-For-Service Negotiations are    on Track  6.10 Fee-For-Service is the Future of the W&D Industry  Chapter 7 Canada and US Drug Reimportation  7.1 Pricing Differential Has Led to Drug Reimportation  7.2 Drugs are Not Always Cheaper in Canada Compared With the US  7.3 Generic Drugs Cheaper in the US and not Canada  7.4 It is Legal for the US to Import Drugs from Canada but only if the     Drugs are Proven Safe  7.4.1 The US Drug Regulators Cannot Guarantee Imported Drug Safety  7.5 The US States Currently Active in US/Canada Drug Reimportation  7.6 Why are Pharmaceutical Prices Lower in Canada?  7.7 Reimportation is a Form of Price Control That May have Poor Financial      Consequences for the Pharmaceutical Industry  7.8 The Response of the Major Drug Companies on Drug Reimportation from     Canada  7.9 The Response of the Canadian Pharmacies to Drug Reimportation  7.10 The Overall Savings from Drug Reimportation for the Consumer and the      US Government is Small  7.11 Drug Reimportation Will Never Work on a Large Scale  Chapter 8 The Big Three US Wholesalers  8.1 The Big Three – Overview  8.2 McKesson – the Leading Wholesaler in the US  8.2.1 Pharmaceutical Solutions  8.2.2 Medical-Surgical Solutions  8.2.3 Information Solutions  8.2.4 Business Switch to Fee-For-Service Model  8.3 Cardinal Health had Revenues of $81bn for the 2007 Financial Year  8.3.1 Pharmaceutical Distribution and Provider Services  8.3.2 Fee-For-Service Move  8.3.3 Cardinal Health and CMS Sign Primary Distribution Agreement for       RFID-enabled Sponge Counting, Detection System  8.4 AmerisourceBergen Will Remain as the Third Largest US Wholesaler  8.4.1 AmerisourceBergen Losses Important VA Contract  8.4.2 ABC Announces $250 Million Accelerated Share Repurchase Transaction  8.4.3 ABC Buys Bellco Health for $190 Million  8.5 Competition Between the Big Three Remains High  Chapter 9 Direct to Pharmacy Distribution in the W&D Industry  9.1 What is Direct to Pharmacy Distribution (DTP)?  9.2 What are the Benefits of This Distribution Model?  9.3 The Concerns of DTP  9.3.1 The Concerns of DTP from the Perspective of Wholesalers  9.3.2 The Concerns of DTP from the Perspective of Pharmacists  9.3.3 The DTP model from the Perspective of the Pharmaceutical       Manufacturers  9.3.4 The Implications of DTP  9.3.5 DTP Adoption Will Affect Competition in the W&D Industry  9.4 DTP Model Will Not Stop Counterfeit Drugs Entering the Pharmaceutical     Supply Chain, Experts Say  9.5 AstraZeneca UK – The Latest Manufacturer to Introduce DTP Distribution  9.6 DTP is Predominately Adopted in the UK Only – Will This Spread Across     the Major Markets?  Chapter 10 Internet Drugs: Mail Order and On-Line Pharmacies  10.1 The Internet – A Relatively New Method of Selling Drugs to the      Consumer  10.2 Use of the Internet Usage has Seen High Growth in Both the Developing      and Developed Countries/Regions  10.3 The US has the Highest Numbers of Internet Users  10.4 Online Pharmacies Offer a Diverse Number of Services  10.5 US Mail Order/On-line Drugs has High Growth  10.6 Online Pharmacies May Need to Diversify their Business Base  10.7 Most US Online Drug Sales are from Women  10.8 Online Drugs and Services May Pose a Significant Health Risk  10.9 Consumers Satisfied with Mail Order  10.10 On-line Prescriptions Facts  10.11 European Online Drug Sales are Low and Limited to OTC  10.12 Online Pharmacy Sites are A Potential Haven for Counterfeiters  10.13 The Verified Internet Pharmacy Practice Site (VIPPS)  Chapter 11 Conclusions – The Pharmaceutical W&D Sector is Undergoing  Significant Change  11.1 High Demand for Pharmaceutical Products Will Drive the W&D Industry  11.1.1 Factors That Will Drive the W&D Industry  11.1.2 Factors That Will Restrain the W&D Industry  11.2 Wholesale Distribution in the European Market Region  11.3 Wholesale Distribution in the US Market Region  11.4 Advantages and Disadvantages for the Fee-For-Service Pricing Strategy  11.5 Despite the Development of Fee-for-Service Both the US and European      W&D Industries will see Continually Low Profit Margins  11.6 Direct-to-Consumer Distribution Channels will Diminish the Role of      Wholesalers  11.7 The Complexity of Wholesale and Distribution Routes Aids the      Counterfeiter  List of Tables  Table 2.1 Types of Wholesalers Described, 2008  Table 2.2 Pharmaceutical retail & hospital breakdown ($bn) in the top           ten countries, 2006  Table 2.3 Pharmaceutical retail & hospital breakdown (%) in the top ten            countries, 2006  Table 3.1 SWOT Analysis of the W&D Industry  Table 4.1 Comparative Drug Prices in Selected Developed Countries  Table 4.2 All Factors that Influence Drug Prices  Table 4.3 Pricing Differentials for Leading Drugs (30 day supply)  Table 5.1 Top Ranked Countries where Counterfeits were Seized/Discovered  Table 7.1 Comparison of Drug Prices Between the US and Canada, 2008  Table 7.2 Comparison of Generic Drug Prices Between the US and Canada, 2008  Table 8.1 Segment breakdown of McKesson’s Revenue, 2007  Table 8.2 McKesson Revenue Forecast ($bn), 2008-2013  Table 8.3 Cardinal Health’s Revenue ($bn) and Operating Margin (%),           2004-2007  Table 8.4 Cardinal Health Revenue Forecast ($bn), 2008-2013  Table 8.5 AmerisourceBergen Revenue Forecast ($bn), 2008-2013  Table 8.6 ABC’s Operating Income and Revenue ($m), 2005-2007  Table 10.1 World Internet Usage and Population Statistics, 2007  Table 10.2 Top Ten Countries with Highest Number of Internet Users, 2007  Table 10.3 Countries with the Highest Internet Penetration Rate, 2007  Table 10.4 US Prescription Sales ($bn) by Distribution Sector, 2007  Table 10.5 Market Share (%) of US Mail Order Revenue of all Prescription            Sales ($bn), 2003-2007  List of Figures  Figure 2.1 Pharmaceutical retail & hospital breakdown ($bn) in the top ten            countries, 2006  Figure 5.1 Flow diagram of how drug counterfeits enter the US supply chain  Figure 8.1 Revenues of the big three US wholesalers ($bn), 2007  Figure 8.2 ABC’s Business Segment Breakdown (%), 2007  Figure 8.3 Revenue Forecasts’ of the Big Three US Wholesalers ($m),            2008-2013  Figure 10.1 US Prescription Sales by Distribution Sector, Market Share (%),             2007  Figure 10.2 Market Share (%) of US Mail Order Revenue of all Prescription             Sales ($bn), 2003-2007 More Details Companies Listed  AAH Pharmaceuticals  Alliance UniChem  American Bank Note Holographics  (ABNH)  AmerisourceBergen Corp. (ABC)  AstraZeneca  British Association of Pharmaceutical  Wholesalers (BAPW)  Cardinal Health (CAH)  Caremark Rx  Celesio  ClearCount Medical Solutions (CMS)  Department of Health (DH)  DIGEMID  Eli Lilly  EMEA  Express Scripts  FDA  FSHSS  GSK  Health and Human Services (HHS)  Health Maintenance Organisations  (HMOs)  IMS  International Pharmaceutical  Manufacturers Group (IPMG)  IWS  McKesson (MCK)  Medco Health Solutions  Medicines and Healthcare Products  Regulatory Agency (MHRA)  MINSA  National Association of Boards of  Pharmacy (NABP)  National Health Service (NHS)  Nielsen  OFT  Patented Medicine Prices Review  Board (PMPRB)  Pembroke Consulting  Pfizer  Pharmaceutical Care Management  Association (PCMA)  Sanofi-Aventis  UniChem Limited  UnitedHealth Group  World Health Organisation (WHO) 

To order this report:

The Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2008

http://www.reportlinker.com/p091996/The-Pharmaceutical-Wholesale-and-Distribution-Industry-Outlook-and-Analysis-2008.html

More market research reports here!

 Contacts: Reportlinker.com Nicolas US: (805) 652-2626 or Int: +1-805-652-2626 Email: nbo@reportlinker.com

SOURCE: Reportlinker.com